Audio Clinical Professionals

Lamotrigine Pharmacokinetics, Safety, and Drug Interactions

This session reviews Lamotrigine Pharmacokinetics, Safety, and Drug Interactions and its most clinically relevant points for exam preparation and bedside decision-making.

This resource is private and requires a subscriber login to stream. SIGN IN to continue.

Duration

00:03:47

File size

0.87 MB

Practitioner-Guided Note

For Lamotrigine Pharmacokinetics, Safety, and Drug Interactions, prioritize Half-life: 24h monotherapy, ~12h with enzyme inducers (carbamazepine/phenobarbital), ~60h with valproate, ~60% protein-bound; extensively hepatically metabolized, and ~10% develop rash; risk higher in children and with valproate when choosing therapy, counseling about risk, planning monitoring, and deciding when closer follow-up or escalation is needed.

Key Takeaways

Half-life: 24h monotherapy, ~12h with enzyme inducers (carbamazepine/phenobarbital), ~60h with valproate; ~60% protein-bound, extensively hepatically metabolized; ~10% develop rash, risk higher in children and with valproate; Saturable phenytoin metabolism &gt,12-15 mcg/mL causes disproportionate level increases; Enzyme induction impairs warfarin-phenytoin interaction